Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

Bibliographic Details
Main Authors:	Alba, E, Albanell, J, de la Haba, J, Barnadas, A, Calvo, L, Sánchez-Rovira, P, Ramos, M, Rojo, F, Burgués, O, Carrasco, E, Caballero, R, Porras, I, Tibau, A, Cámara, M C, Lluch, A
Format:	Online
Language:	English
Published:	Nature Publishing Group 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950860/

Similar Items

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial
by: Martin, Miguel, et al.
Published: (2014)

Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study
by: de Dueñas, Eduardo Martínez, et al.
Published: (2014)

Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells
by: OKITA, RIKI, et al.
Published: (2015)

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation
by: Wang, Yen-Chao, et al.
Published: (2011)

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
by: Gallardo, A, et al.
Published: (2012)

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
by: Peiró, G, et al.
Published: (2014)

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ
by: Estévez, Laura G, et al.
Published: (2014)

Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case–control EpiGEICAM study
by: Castelló, A, et al.
Published: (2014)

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
by: Moreno-Aspitia, Alvaro, et al.
Published: (2013)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
by: Cristofanilli, Massimo, et al.
Published: (2012)

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial
by: Witzel, I, et al.
Published: (2012)

The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis
by: Chen, Zhe-Ling, et al.
Published: (2016)

Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study
by: Hammerman, Ariel, et al.
Published: (2015)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
by: Leung, Wing-yin, et al.
Published: (2015)

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor
by: Spector, Neil L., et al.
Published: (2015)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
by: De Silva, Nadeera, et al.
Published: (2015)

Metastatic, Her-2 Amplified Lacrimal Gland Carcinoma with Response to Lapatinib Treatment
by: Dennie, Trevor
Published: (2015)

Adjuvant trastuzumab in HER2-positive breast cancer.
by: Slamon, D., et al.
Published: (2011)

Targeting HER2 in breast cancer: beyond trastuzumab
by: Winer, EP
Published: (2011)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
by: Nahta, Rita, et al.
Published: (2006)

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
by: Wang, Leiping, et al.
Published: (2011)

Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis
by: Guérin, Annie, et al.
Published: (2014)

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA†
by: Krop, I. E., et al.
Published: (2015)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
by: Fiszman, Gabriel L., et al.
Published: (2011)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
by: Sadeghi, Saeed, et al.
Published: (2014)

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer
by: Alba, Emilio, et al.
Published: (2016)

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2014)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
by: Palmieri, Carlo, et al.
Published: (2015)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
by: Canonici, Alexandra, et al.
Published: (2013)

Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)
by: Quintela-Fandino, M, et al.
Published: (2014)

t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib
by: Christenson, Jessica L., et al.
Published: (2015)

Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors
by: Lin, Chun-Han, et al.
Published: (2015)

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib
by: Oliveras-Ferraros, Cristina, et al.
Published: (2011)

Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy
by: Ahn, Eugene R., et al.
Published: (2012)

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study
by: Gori, Stefania, et al.
Published: (2016)

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
by: Martin, Miguel, et al.
Published: (2016)

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer
by: Kaufman, Bella, et al.
Published: (2008)

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
by: Brain, E, et al.
Published: (2012)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
by: Green, Andrew R., et al.
Published: (2014)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
by: Jeyakumar, Alwin, et al.
Published: (2012)